Haemonetics (NYSE:HAE) updated its FY 2020 earnings guidance on Tuesday. The company provided earnings per share (EPS) guidance of $2.80-3.00 for the period, compared to the Thomson Reuters consensus estimate of $2.89. The company issued revenue guidance of $1.016-1.035 billion, compared to the consensus revenue estimate of $1.04 billion.
Several brokerages have commented on HAE. Zacks Investment Research downgraded Haemonetics from a hold rating to a sell rating in a research report on Thursday, January 24th. ValuEngine downgraded Haemonetics from a strong-buy rating to a buy rating in a research report on Tuesday, February 5th. Finally, Barrington Research lifted their price target on Haemonetics to $112.00 and gave the stock a positive rating in a research report on Wednesday, February 6th. One equities research analyst has rated the stock with a hold rating and four have assigned a buy rating to the stock. Haemonetics has an average rating of Buy and an average price target of $119.75.
HAE opened at $93.86 on Tuesday. The company has a market cap of $4.77 billion, a PE ratio of 50.19, a PEG ratio of 2.44 and a beta of 0.85. The company has a current ratio of 2.44, a quick ratio of 1.64 and a debt-to-equity ratio of 0.51. Haemonetics has a 1 year low of $76.13 and a 1 year high of $117.56.
Haemonetics (NYSE:HAE) last released its quarterly earnings data on Tuesday, February 5th. The medical instruments supplier reported $0.63 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.59 by $0.04. The business had revenue of $247.36 million for the quarter, compared to analysts’ expectations of $250.12 million. Haemonetics had a return on equity of 17.05% and a net margin of 4.84%. Haemonetics’s quarterly revenue was up 5.7% on a year-over-year basis. During the same period in the previous year, the business posted $0.62 earnings per share. As a group, research analysts predict that Haemonetics will post 2.33 earnings per share for the current year.
In other news, Director Ronald G. Gelbman sold 8,196 shares of the business’s stock in a transaction that occurred on Friday, February 15th. The stock was sold at an average price of $86.52, for a total transaction of $709,117.92. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, EVP Michelle L. Basil sold 391 shares of the business’s stock in a transaction that occurred on Thursday, March 7th. The shares were sold at an average price of $83.57, for a total value of $32,675.87. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 11,909 shares of company stock worth $1,036,501. 1.04% of the stock is currently owned by company insiders.
Haemonetics Corporation, a healthcare company, provides hematology products and solutions. The company operates through five segments: North America Plasma; Americas Blood Center and Hospital; Europe, Middle East and Africa; Asia Pacific; and Japan. It offers automated plasma collection devices and related disposables, including NexSys PCS plasmapheresis system and PCS2 equipment and disposables, plasma collection containers, and intravenous solutions, as well as information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system.
Further Reading: Moving Average Convergence Divergence (MACD)
Receive News & Ratings for Haemonetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Haemonetics and related companies with MarketBeat.com's FREE daily email newsletter.